Strides Pharma Science today announced that its wholly-owned subsidiary, Strides Pharma Global Pte Ltd (Singapore) has received approval for Oxybutynin Chloride tablets USP, 5 mg from United States Food & Drug Administration (USFDA). The tablet is therapeutically and bioequivalent equivalent to the reference listed drug (RLD), Ditropan tablets, 5 mg, of Janssen Pharmaceuticals, Inc.